Daesung Microbiological Laboratories Co., Ltd.

As of March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. carries a market capitalization of 29.91B, placing it among publicly traded companies globally. Its enterprise value stands at 40.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. has 3.80M shares outstanding.

As of March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. trades at a trailing price-to-earnings ratio of 45.75. The price-to-sales ratio is 1.16, and the price-to-book ratio stands at 0.86.

As of March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. trades at an EV/EBITDA multiple of 13.15 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 75.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 40.29B versus a market cap of 29.91B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. maintains a current ratio of 2.97, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 56.72, indicating elevated leverage, while an interest coverage ratio of 10.41 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. posted a return on equity (ROE) of 1.88, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 1.13, measuring how efficiently the asset base is converted into earnings. The company generates approximately 186.78M in revenue per employee across its workforce of 138.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.74 indicates how many times Daesung Microbiological Laboratories Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. recorded an income tax benefit of -255.97M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 397.75M, leaving 653.72M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Daesung Microbiological Laboratories Co., Ltd.'s stock has declined approximately 24.30% over the past 52 weeks. The 50-day moving average sits at 6,074.60, while the 200-day moving average is 6,797.05.

Over the twelve months ended March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. generated 25.87B in revenue and converted that into 653.72M in net income, yielding earnings per share of 172.03. EBITDA reached 3.06B, while operating income came in at 532.91M.

As of March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. holds 9.43B in cash and equivalents against 19.81B in total debt, resulting in a net debt position of 16.21B. Total book value stands at 34.93B, with working capital of 16.54B providing operational flexibility.

Daesung Microbiological Laboratories Co., Ltd. produced 1.78B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -375.32M in capital expenditures, free cash flow totaled 1.41B - equivalent to 370.75 per share.

Over the twelve months ended March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. posted a gross margin of 24.61, reflecting its pricing power and cost economics. The operating margin of 2.06 and net profit margin of 2.53 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.71, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.83, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Daesung Microbiological Laboratories Co., Ltd. shareholders.

Daesung Microbiological Laboratories Co., Ltd.'s most recent stock split took place on May 16, 2018 with a 1:10 split ratio.

As of March 31, 2026, Daesung Microbiological Laboratories Co., Ltd. has an Altman Z-Score of 2.29, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.